Bupron SR is a branded medication that contains bupropion as its active component. It belongs to the antidepressant and smoking-cessation classes of drugs. The product is supplied as a 150 mg sustained-release (SR) pill. In Hong Kong, Bupron SR is a prescription-only medication and is regulated by the Hong Kong Department of Health. Generic versions of bupropion are also available and are marketed under various brand names.
Bupropion acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI). By blocking the transporters that remove norepinephrine and dopamine from nerve endings, the drug increases the levels of these neurotransmitters in the brain. Higher dopamine activity helps reduce cravings for nicotine, while enhanced norepinephrine contributes to mood elevation. The sustained-release formulation allows a steady plasma concentration, providing a smoother onset of effect and reducing the peak-related side effects that can occur with immediate-release tablets.
Bupron SR is approved in Hong Kong for the following indications:
These approvals are aligned with the assessments of the Hong Kong Department of Health, which follows international standards for safety and efficacy. The medication is intended for adult patients; use in children and adolescents is not recommended without specialist supervision.
Research has explored several off-label applications of bupropion. While these uses are not approved by Hong Kong regulatory agencies, they have been examined in peer-reviewed studies:
Off-label use requires medical supervision and individualized risk assessment. Patients should discuss potential benefits and risks with a qualified healthcare professional before initiating such therapy.
Regular follow-up appointments enable personalised dose optimisation and early identification of adverse effects.
This article provides educational information about Bupron SR and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Bupron SR can be taken with or without food. Consistent timing each day helps maintain steady drug levels, but taking it with a small amount of food may reduce occasional stomach upset.
Bupron SR uses a sustained-release matrix that delivers the medication slowly over time, allowing once-daily dosing and minimizing peak-related side effects compared with immediate-release formulations that require multiple daily doses.
Clinical studies have shown that bupropion, the active ingredient in Bupron SR, can double the chances of quitting smoking when combined with counseling. It is an approved smoking-cessation aid in Hong Kong.
Most patients notice an improvement in depressive symptoms within 2 to 4 weeks, but full therapeutic effects may take up to 6 weeks. Patience and regular follow-up are important during this period.
Bupropion can cause a modest increase in blood pressure, especially at higher doses. Patients with pre-existing hypertension should have their blood pressure monitored after starting therapy.
Moderate alcohol consumption is not strictly prohibited, but excessive drinking can lower the seizure threshold and increase the risk of seizures. Limiting alcohol intake is advisable.
If you remember the missed dose within 12 hours, take it promptly. If it is close to the time of your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Do not double the dose.
Older adults may be more sensitive to stimulant effects such as insomnia or dizziness. Initiating therapy at the lowest possible dose and monitoring for side effects is recommended.
Unlike selective serotonin reuptake inhibitors (SSRIs), Bupron SR primarily increases norepinephrine and dopamine levels, which can be beneficial for patients who experience sexual side effects or weight gain with SSRIs. Choice of therapy should be individualized based on symptom profile and tolerability.
Coverage varies by individual insurance plans and public subsidy programs. Patients should verify their eligibility with their health insurance provider or the Hong Kong Hospital Authority.